Kimberly Smith, ViiV via Youtube

They went from dai­ly to once every two months. But how much longer act­ing can HIV meds be? Vi­iV en­lists Halozyme's tech to find out

It wasn’t easy nav­i­gat­ing the man­u­fac­tur­ing and con­trols is­sues that had led the FDA to re­ject Vi­iV Health­care’s first pitch for the once-month­ly HIV reg­i­men cabote­gravir and rilpivirine. But even as Kim­ber­ly Smith was knee-deep in sort­ing out those prob­lems and putting to­geth­er a new pack­age that fi­nal­ly won the reg­u­la­tors over this Jan­u­ary, her busi­ness de­vel­op­ment team kept look­ing for things that would take them to the next lev­el.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.